Sex, no. (%)
| | |
0.075
| | |
0.581
|
0.910
|
From male patients
|
44 (16.73)
|
35 (13.31)
| |
21 (7.98)
|
20 (7.60)
| | |
From female patients
|
45 (17.11)
|
61(23.19)
| |
17 (6.46)
|
20 (7.60)
| | |
Age/mean ± SD, years
|
58.35 ± 6.76
|
59.23 ± 7.55
|
0.406
|
58.37 ± 8.22
|
58.55 ± 10.09
|
0.931
|
0.745
|
Pathology source (no. (%))
| | |
0.294
| | |
0.502
|
0.228
|
SCC
|
25 (9.88)
|
20 (6.84)
| |
9 (3.42)
|
12 (4.74)
| | |
Adenocarcinoma
|
62 (24.51)
|
76 (28.90)
| |
28 (11.07)
|
28 (10.65)
| | |
NEC
|
1 (0.38)
|
0 (0.00)
| |
1 (0.38)
|
0 (0.00)
| | |
Sarcoma
|
1 (0.38)
|
0 (0.00)
| |
0 (0.00)
|
0 (0.00)
| | |
LN station (no. (%))
| | |
0.048
| | |
0.002
|
0.208
|
#1, #2
|
10 (3.80%)
|
4 (1.52%)
| |
7 (2.66%)
|
0 (0.00%)
| | |
#3–9
|
32 (12.17%)
|
49 (18.63%)
| |
15 (5.70%)
|
10 (3.80%)
| | |
#10–14
|
47 (17.87%)
|
43 (16.35%)
| |
16 (6.08%)
|
30 (11.41%)
| | |
Lung lobe (no. (%))
| | |
0.046
| | |
0.420
|
0.847
|
Right upper lobe
|
25 (9.51%)
|
28 (10.65%)
| |
10 (3.80%)
|
9 (3.42%)
| | |
Right middle lobe
|
4 (1.52%)
|
16 (6.08%)
| |
4 (1.52%)
|
5 (1.90%)
| | |
Right lower lobe
|
17 (6.46%)
|
21 (7.98%)
| |
8 (3.04%)
|
9 (3.42%)
| | |
Left upper lobe
|
17 (6.46%)
|
14 (5.32%)
| |
11 (4.18%)
|
6 (2.28%)
| | |
Left lower lobe
|
26 (9.89%)
|
17 (6.46%)
| |
5 (1.90%)
|
11 (4.18%)
| | |
SUVmax/median (25%, 75%)
|
3.95 (2.92, 6.54)
|
2.29 (1.51, 3.50)
|
< 0.001
|
4.15 (3.28, 8.68)
|
2.22 (3.16, 3.42)
|
< 0.001
|
0.759
|
SAD/median (25%,75%) (cm)
|
1.00 (0.80, 1.38)
|
0.90 (0.70, 1.00)
|
< 0.001
|
1.05 (0.90, 1.35)
|
0.80 (0.60, 1.08)
|
< 0.001
|
0.754
|
Rad-Score
|
0.582 (− 0.221, 1.892)
|
− 0.808 (− 1.779, − 2.000)
|
< 0.001
|
0.702 (0.255, 1.991)
|
− 0.677(− 1.230, 0.228)
|
< 0.001
|
0.242
|
Int-Score
|
1.387 (− 0.014, 3.109)
|
− 1.438 (− 2.402, − 0.293)
|
< 0.001
|
1.405 (− 0.030, 3.060)
|
− 1.297 (− 2.422, − 0.119)
|
< 0.001
|
0.449
|